NuCana to Participate in Citi's 17th Annual BioPharma Conference
August 31, 2022 08:00 ET
|
NuCana plc
EDINBURGH, United Kingdom, Aug. 31, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that management will host one-on-one meetings at Citi's 17th Annual BioPharma Conference. ...
NuCana Reports Second Quarter 2022 Financial Results and Provides Business Update
August 17, 2022 16:01 ET
|
NuCana plc
Multiple Data Readouts on Track for the Second Half of 2022 and the First Half of 2023 Well Capitalized with Anticipated Cash Runway into 2025 EDINBURGH, United Kingdom, Aug. 17, 2022 (GLOBE...
NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement
July 27, 2022 08:00 ET
|
NuCana plc
EDINBURGH, United Kingdom, July 27, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), (“NuCana” or the “Company”), announced that it has received a written notification (the “Notification Letter”)...
German Court Rules that Gilead’s Sofosbuvir Infringes NuCana’s ‘190 Patent
July 11, 2022 08:00 ET
|
NuCana plc
EDINBURGH, United Kingdom, July 11, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that, following a comprehensive hearing on May 17, 2022, the Regional Court of Dusseldorf (the...
NuCana Announces Presentation on NUC-7738 at the European Hematology Association (EHA) 2022 Hybrid Congress
June 10, 2022 07:00 ET
|
NuCana plc
NUC-7738 Shows Promising Non-Clinical Activity in Acute Myeloid Leukemia NUC-7738 Kills AML Cells Resistant to Standard Chemotherapy Data Indicates Potential Clinical Utility Beyond Solid Tumors ...
NuCana Announces Receipt of NASDAQ Notice
June 03, 2022 16:01 ET
|
NuCana plc
EDINBURGH, United Kingdom, June 03, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that it received written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC...
NuCana Reports First Quarter 2022 Financial Results and Provides Business Update
June 02, 2022 16:01 ET
|
NuCana plc
Initiated Randomized Phase 2 Study of NUC-3373 in Patients with Colorectal Cancer Initiated Phase 1b/2 Study of NUC-3373 in Combination with Other Agents, Including PD-1 Inhibitors, in Patients...
NuCana to Participate in the 2022 Jefferies Healthcare Conference
June 01, 2022 16:01 ET
|
NuCana plc
EDINBURGH, United Kingdom, June 01, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Don Munoz, Chief Financial Officer, will host one-on-one meetings at the Jefferies...
NuCana Reports Fourth Quarter and Year Ended 2021 Financial Results and Provides Business Update
April 27, 2022 16:01 ET
|
NuCana plc
Optimizes Development Strategy with Study Initiations and Data Announcements Expected throughout 2022 Announces Plan to Initiate Randomized Phase 2 Study for NUC-3373 in Colorectal Cancer Extends...
NuCana Announces Upcoming Presentations on NUC-3373 at the American Association for Cancer Research (AACR) Annual Meeting 2022
March 08, 2022 16:35 ET
|
NuCana plc
Checkpoint Inhibitor Nivolumab Activity Enhanced by NUC-3373 in vitro NUC-3373 Shown to be a More Efficient DNA Damaging Agent in Cancer Cells than 5-FU NUC-3373 Did Not Generate Metabolites...